News
UCB announces approval of Bimzelx
UCB has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for Bimzelx, also known as bimekizumab.
You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.
UCB has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for Bimzelx, also known as bimekizumab.